Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-4998

Weiterlesen

Ad hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-5593

Weiterlesen

Twelfth Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/twelfth–milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-received-4994

Weiterlesen

Acquisition of Kinaxo Biotechnologies GmbH completed

Evotec AG today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/acquisition-of-kinaxo-biotechnologies-gmbh-completed-4990

Weiterlesen

Evotec Establishes Research Collaboration With Harvard University and the Howard Hughes Medical Institute in Diabetes Research

Evotec AG today announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute aimed at discovering and developing new  treatments in the field of diabetes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-establishes-research-collaboration-with-harvard-university-and-the-howard-hughes-medical-institute-in-diabetes-research-4984

Weiterlesen